


Claims

1. Compounds of the general formula I


5



Formula I


wherein

R1 represents the groups



10

whereby in these groups R⁵ is hydrogen, lower alkyl with 1 to 4 carbon atoms, or the group



15

wherein

R⁸ represents, lower alkyloxy, lower alkylamino, or lower alkyl with 1 to 4 carbon atoms;

R⁹ represents, lower alkyl with 1 to 4 carbon atoms;

20 R⁸ and R⁹ together form a 5- or 6- membered heterocyclic ring containing one to two hetero atoms which can be the same or different and are oxygen or nitrogen.

R⁶ represent hydrogen, halogen, nitro, or lower alkyloxy;

R^7 represents hydrogen;


R^2 and R^3 independently represent hydrogen; lower alkyl with 1 to 3 carbon atoms; or together a lower alkylene group with 1 to 3 carbon atoms bridging the oxygen atoms
5 and forming a five, six or seven membered ring;

R^4 represents hydrogen;

and pharmaceutically acceptable salts thereof.

10

2. Compounds of the general formula I'




Formula I'

15 wherein

R¹ represents the groups



20 whereby in these groups R⁵ is hydrogen, lower alkyl with 1 to 4 carbon atoms, or the group



wherein

R⁸ represents, lower alkyloxy, or lower alkyl with 1 to 4 carbon atoms;

R⁹ represents, lower alkyl with 1 to 4 carbon atoms;

R⁸ and R⁹ together form a 5- or 6- membered heterocyclic ring containing one to two hetero atoms which can be the same or different and are oxygen or nitrogen.

5

R⁶ represent hydrogen, halogen, nitro, or lower alkyloxy;

R⁷ represents hydrogen;

10 R² and R³ independently represent hydrogen; lower alkyl with 1 to 3 carbon atoms; or together a lower alkylene group with 1 to 3 carbon atoms bridging the oxygen atoms and forming a five, six or seven membered ring;


R⁴ represents hydrogen;

15

and pharmaceutically acceptable salts thereof.

3. Compounds of the general formula II

20



wherein

R² and R³ represent methyl;


25 R⁴ represents hydrogen;

R⁵ and R⁶ are as defined in formula I;

R⁷ represents hydrogen;

and pharmaceutically acceptable salts thereof.

4. Compounds of the general formula III




5 wherein

R² and R³ represent methyl;R⁴ represents hydrogen;R⁵ and R⁶ are as defined in formula I;R⁷ represents hydrogen;

10

and pharmaceutically acceptable salts thereof.

5. Compounds of the general formula IV



15

wherein

R² and R³ represent methyl;R⁴ represents hydrogen;20 R⁵ and R⁶ are as defined in formula I;R⁷ represents hydrogen;

and pharmaceutically acceptable salts thereof.

6. Compounds selected from the group consisting of:

5

5-[6,7-Dimethoxy-2-(7-methoxy-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;

5-[6,7-Dimethoxy-2-(5-methoxy-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;

10 5-[2-(1H-Indol-3-ylmethyl)-6,7-dimethoxy-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;

5-[6,7-Dimethoxy-2-(2-methyl-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;

15 5-[2-(6-Fluoro-1H-indol-3-ylmethyl)-6,7-dimethoxy-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;

{3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indol-2-yl}-morpholin-4-yl-methanone;

3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid dimethylamide;

20 5-[6,7-Dimethoxy-2-(5-nitro-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;

{3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indol-2-yl}-pyrrolidin-1-yl-methanone;

25 3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-5-methoxy-1H-indole-2-carboxylic acid dimethylamide;

3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid methoxy-methyl-amide;

5-Chloro-3-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid dimethylamide;

30 3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-5-fluoro-1H-indole-2-carboxylic acid dimethylamide;


5-Chloro-3-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid methoxy-methyl-amide;

35 3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid N,N'-dimethyl-hydrazide;


3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-5-fluoro-1H-indole-2-carboxylic acid methoxy-methyl-amide;

and pharmaceutically acceptable salts thereof.

7. intermediates of the general formula **XI** and **XII**.



XI



XII

wherein R^2 , R^3 , R^4 , R^5 and R^6 have the meaning given in formula I in claim 1 and 2.

8. Pharmaceutical compositions comprising one or more compounds of any one of claims 1 to 6 and usual inert carrier materials.

9. Pharmaceutical compositions for the treatment of of infections caused by Gram positive or Gram negative pathogens comprising one or more compounds of any one of claims 1 to 6 and usual inert carrier materials.

10. The compounds of any one of claims 1 to 6 for use as medicaments.

11. The compounds of any one of claims 1 to 6 for use as medicaments for the treatment of infection,

12. The compounds of any one of claims 1 to 6 for use as medicaments for the treatment of infection caused by Gram positive or Gram negative pathogens or by a mixture thereof.

13. The use of one or more compounds of any one of claims 1 to 6 as active ingredients for the production of pharmaceutical compositions.

14. The use of one or more compounds of any one of claims 1 to 6 as active ingredients for the production of pharmaceutical compositions for the treatment of infections.

15. The use of one or more compounds of any one of claims 1 to 6 as active ingredients for the production of pharmaceutical compositions for the treatment of infections caused by Gram positive or Gram negative pathogens or by a mixture thereof.

16. A process for the manufacture of pharmaceutical compositions containing one or more compounds as claimed in any one of claims 1 to 6 as active ingredients which process comprises mixing one or more active ingredients with pharmaceutically acceptable inert carrier materials and adjuvants in a manner known per se.

17. A process for the manufacture of pharmaceutical compositions for the treatment of infections caused by Gram positive or Gram negative pathogens or by a mixture thereof containing one or more compounds as claimed in any one of claims 1 to 6 as active ingredients which process comprises mixing one or more active ingredients with pharmaceutically acceptable inert carrier materials and adjuvants in a manner known per se.